Global Hepatitis B Immune Globulin Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hepatitis B Immune Globulin Market Insights, Forecast to 2034
Hepatitis B immune globulin (HBIG) is a type of blood product made from human plasma that contains antibodies against the hepatitis B virus. It is typically given by injection and is used to prevent or treat hepatitis B infection
Global Hepatitis B Immune Globulin market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Hepatitis B Immune Globulin industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Hepatitis B Immune Globulin key manufacturers include ADMA Biologics, Bio Products Laboratory, Grifols, Biotest AG, CSL Behring, FFF Enterprises and Cleveland Clinic, etc. ADMA Biologics, Bio Products Laboratory, Grifols are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Hepatitis B Immune Globulin were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Hepatitis B Immune Globulin market and estimated to attract more attentions from industry insiders and investors.
Hepatitis B Immune Globulin can be divided into Intravenous Injection and Intramuscular Injection, etc. Intravenous Injection is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Hepatitis B Immune Globulin is widely used in various fields, such as Liver Transplant Patients, Newborn Baby and Others,, etc. Liver Transplant Patients provides greatest supports to the Hepatitis B Immune Globulin industry development. In 2022, global % sales of Hepatitis B Immune Globulin went into Liver Transplant Patients filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Hepatitis B Immune Globulin market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Hepatitis B Immune Globulin market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
ADMA Biologics
Bio Products Laboratory
Grifols
Biotest AG
CSL Behring
FFF Enterprises
Cleveland Clinic
Segment by Type
Intravenous Injection
Intramuscular Injection
Liver Transplant Patients
Newborn Baby
Others
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Hepatitis B Immune Globulin plant distribution, commercial date of Hepatitis B Immune Globulin, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Hepatitis B Immune Globulin introduction, etc. Hepatitis B Immune Globulin Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Hepatitis B Immune Globulin
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Hepatitis B Immune Globulin market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Hepatitis B Immune Globulin industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Hepatitis B Immune Globulin key manufacturers include ADMA Biologics, Bio Products Laboratory, Grifols, Biotest AG, CSL Behring, FFF Enterprises and Cleveland Clinic, etc. ADMA Biologics, Bio Products Laboratory, Grifols are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Hepatitis B Immune Globulin were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Hepatitis B Immune Globulin market and estimated to attract more attentions from industry insiders and investors.
Hepatitis B Immune Globulin can be divided into Intravenous Injection and Intramuscular Injection, etc. Intravenous Injection is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Hepatitis B Immune Globulin is widely used in various fields, such as Liver Transplant Patients, Newborn Baby and Others,, etc. Liver Transplant Patients provides greatest supports to the Hepatitis B Immune Globulin industry development. In 2022, global % sales of Hepatitis B Immune Globulin went into Liver Transplant Patients filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Hepatitis B Immune Globulin market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Hepatitis B Immune Globulin market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
ADMA Biologics
Bio Products Laboratory
Grifols
Biotest AG
CSL Behring
FFF Enterprises
Cleveland Clinic
Segment by Type
Intravenous Injection
Intramuscular Injection
Segment by Application
Liver Transplant Patients
Newborn Baby
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Hepatitis B Immune Globulin plant distribution, commercial date of Hepatitis B Immune Globulin, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Hepatitis B Immune Globulin introduction, etc. Hepatitis B Immune Globulin Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Hepatitis B Immune Globulin
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices